Edwards Lifesciences (EW) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $52.32B | Exchange | NYSE |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Bernard J. Zovighian |
| IPO Date | 2000-03-27 | CAGR | 7.59% |
| Employees | 16,000 | Website | www.edwards.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.15% | Total Yield | 0.15% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $56.89B | P/E | 33.66 | Forward P/E | 26.9 | PEG | -2.12 |
| P/S | 42.3 | P/B | 26.65 | P/CF | 202.84 | P/FCF | 252.72 |
| Sales | $6.51B | Sales 1Y | 14.55% | Sales 3Y | 20.1% | Sales 5Y | 32.22% |
| EPS | $2.7 | EPS 1Y | -74.96% | EPS 3Y | -23.01% | EPS 5Y | -25.32% |
| Sales QoQ | 5.6% | EPS QoQ | -36.36% | Sales QoQ Avg | 3.27% | EPS QoQ Avg | 49.36% |
| Gross Margin | 77.98% | Operating Margin | 28.09% | Profit Margin | 15.43% | ROCE | 15.36% |
| ROA | 8% | ROE | 10% | Altman Z Score | 13.55 | Piotroski Score | 5 |
| Current Ratio | 4.42 | Quick Ratio | 3.63 | Cash Ratio | 1.74 | Op. CF Ratio | 0.03 |
| Debt/Equity | 0.07 | Debt/Assets | 0.05 | Lt Debt/Equity | 0.07 | Lt Debt/Cap. | 0.05 |
| Intrst Cov. | — | Inventory Turnover | 1.28 | Asset Turnover | 0.49 | Receivables Turnover | 6.69 |
| Enterprise Value | $56.89B | P/E Ratio | 33.66 |
| Forward P/E | 26.9 | PEG Ratio | -2.12 |
| P/S Ratio | 42.3 | P/B Ratio | 26.65 |
| P/CF Ratio | 202.84 | P/FCF Ratio | 252.72 |
| EPS | $2.7 | EPS Growth 1Y | -74.96% |
| EPS Growth 3Y | -23.01% | EPS Growth 5Y | -25.32% |
| Revenue Growth 1Y | 14.55% | Gross Margin | 0.78% |
| Operating Margin | 0.28% | Profit Margin | 0.15% |
| ROE | 0.1% | ROA | 0.08% |
| ROCE | 0.15% | Current Ratio | 4.42 |
| Quick Ratio | 3.63 | Cash Ratio | 1.74 |
| Debt/Equity | 0.07 | Interest Coverage | — |
| Altman Z Score | 13.55 | Piotroski Score | 5 |
Edwards Lifesciences (EW) valuation & financials
Edwards Lifesciences (EW) has a market capitalization of $52.32B and trades at a price-to-earnings ratio of 33.7. It operates in the Healthcare sector (Medical - Devices).
Edwards Lifesciences's revenue grew +14.6% over the last year.
Edwards Lifesciences's next earnings report is scheduled for October 29, 2026 after market close; analysts estimate EPS of $0.73. Check the earnings calendar to see all companies reporting this week.
Edwards Lifesciences (EW) — frequently asked questions
When does Edwards Lifesciences (EW) report earnings next?
Edwards Lifesciences is expected to report earnings on October 29, 2026 after market close. Analysts estimate EPS of $0.73.
What is Edwards Lifesciences's market cap?
Edwards Lifesciences (EW) has a market capitalization of $52.32B.
What is EW's P/E ratio?
Edwards Lifesciences trades at a price-to-earnings ratio of 33.7, with trailing twelve-month EPS of $2.70.
How fast is Edwards Lifesciences growing?
Edwards Lifesciences's revenue grew +14.6% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · Merck (MRK) · UnitedHealth (UNH) · Roche (ROG.SW)